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Introduction
Juvenile Nasopharyngeal Angiofibroma (JNA) 
is a mesenchymal tumor with its constituent 
tissue originating from the stromal and 
blood vessels with dense collagen. The tumor 
predominantly arises from the superior 
part of the sphenopalatine foramen and the 
posterolateral wall of the nasopharynx.1 
Juvenile Nasopharyngeal Angiofibroma is a 
histologically benign, but clinically malignant 
tumor because it can damage the bone and 
extend to the surrounding tissue.2,3
The incidence of JNA is 0.05–0.5% of all head 
and neck tumors and is relatively occurred 
more in India and Egypt compared to America 
and Europe. Moreover, in Asia, the incidence 
is around 1: 5,000 while in the Middle East 1: 
60,000. These lesions are almost always found 
in adolescent male patients, in the age range of 
9–19 years with the highest incidence between 
the ages of 14–18 years.4–6 In Indonesia, JNA is 
reported 2 to 4 cases in 1 year.7 At Dr. Hasan 
Sadikin General Hospital Bandung, there were 
112 JNA patients for the period of 2011–2018 
with 111 male and 1 female, and most of them 
were in the age range of 10–20 years.8
The staging of the tumor can be seen from 
the CT scan results with the classification 
system based on the expansion of the tumor; 
the higher the clinical stage, and the more 
extensive lesions caused. The most commonly 
used and developed system in recent 
literature is the Radkowski classification. 
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Abstract
Background: Juvenile Nasopharyngeal Angiofibroma (JNA) is a benign tumor of mesenchymal tissue, 
originating from the stromal and blood vessels with dense collagen. However, JNA has a malignant 
tumor-like property because it can cause erosion of surrounding bone. Vascular Endothelial Growth 
Factor (VEGF) plays a role in the angiogenesis process. The expression of VEGF is the best marker 
to determine the occurrence of angiogenesis in JNA. This study aimed to determine the correlation 
between VEGF expression and JNA clinical stage. 
Methods: This was a cross-sectional correlational analytic observational study on medical records 
and paraffin blocks of all patients with JNA at Dr. Hasan Sadikin General Hospital Bandung during the 
period of 2016 to 2019. Immunohistochemistry examination of VEGF expressions was performed and 
VEGF expression was rated based on staining intensity, percentage distribution, and histoscore. Data 
were then analyzed using the Spearman correlation test.
Results: Of 24 patients, 23 males and 1 female, 58% demonstrated a strong intensity of staining. The 
positivity of VEGF cell percentage was identified as 26–50% (n=6 patients), 51–75% (n=11), and 
>75% (n=7). The median VEGF histoscores were 2.5, 6.5, and 12 in JNA stage I, stage II, and stage 3, 
respectively, with the greater VEGF histoscore had a higher clinical stage with a correlation coefficient 
of (rs) 0.723 (p=0.002). 
Conclusions: There is a strong correlation between increased VEGF expression and JNA clinical stage. 
VEGF expression can be used as a prognostic factor of JNA.
Keywords: Angiogenesis, juvenile nasopharyngeal angiofibroma, staging, vascular endothelial growth 
factor
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This assessment includes the extension to the 
posterior pterygoid and the rate of skull base 
erosion. This system considers the choice of 
surgical approach and the risk of recurrence.4,5
The cause of JNA is not yet clearly known, 
being genetic factors, molecular alterations, 
HPV infections, and related to hormones 
that may play an important role in JNA 
development.9 The Growth of tumor tissue 
is related to increased estrogen production 
and reduced production of androgen 
hormones.10 Furthermore, JNA has biological 
characteristics of angiogenic histogenetic 
tumors.11 Various attempts to determine 
tumor pathogenesis have been carried out by 
studying the expression of growth factors and 
oncogenes such as C-KIT and C-MYC. Those 
studies support that vascular endothelial cells 
can become postembryonic undifferentiated 
mesenchyme cells and can be induced into 
other mesenchymal non-hemopoietic cell 
phenotypes. The GSTM1 gene has been 
involved in the formation of JNA. Loss of 
GSTM1 expression or null genotype has been 
observed in these tumors.
Angiogenesis in tumors is influenced by 
angiogenic factors such as basic Fibroblast 
Growth Factor (bFGF), Vascular Endothelial 
Growth Factor (VEGF), angiogenin, 
Transforming Growth Factor (TGF), 
thrombopoietin, angiopoietin I, cytokines, 
angiogenic enzymes, and indirect activated 
activation factor. The VEGF encourages 
enzymes and proteins that are important 
for the process of degradation of the basic 
membrane, useful for endothelial cells for 
migration and invasion which are important 
stages in angiogenesis. Overexpression of 
VEGF is associated with tumor progression 
and prognosis in various tumors, including 
JNA. Furthermore, the VEGF contributes to 
proliferation and suggests the promotion of 
vascularity. The increased neovascularization, 
decreased apoptosis, and increased endothelial 
cell proliferation may lead to progressive and 
increased clinical stages.12,13
Study on immunohistochemical 
examination for the VEGF, TGFβ, estrogen 
and progesterone receptors (ER-PR), and 
proliferating cell nuclear antigen (PCNA), taken 
from anatomic pathological preparations of 
JNA patients has shown that VEGF, TGFβ, and 
PCNA are widely expressed in JNA tissue, and 
are positively related to the clinical stage and 
the prognosis of JNA.14 
The expression and subcellular distribution 
of several angiogenesis factors have been 
studied such as TGFβ, bFGF, VEGF-R 1-2, and 
Hypoxia Inducible Factor (HIF-1α).15 The 
results show that the growth of vascularization 
and the progression of the clinical stage of 
JNA are influenced by factors released by 
fibroblasts in the stroma. However, the effect 
of VEGF is still debatable. Interestingly, VEGF 
expression is not significantly related to the 
puberty status, stage of the tumor, intra-
operative blood loss, and the recurrence of the 
JNA.16
The VEGF has a central role in the pathways 
and stages of tumor angiogenesis, and 
especially the degradation of extracellular 
matrix and proliferation of vascular endothelial 
cells. Increased endothelial cell proliferation 
will further increase microvascular density 
as well as increase VEGF expression. The 
VEGF expression is the best marker for 
determining the precence of angiogenesis in 
JNA.15 Therefore, the aim of this study was 
to determine the correlation between VEGF 
expression and the clinical stage of JNA.
Methods
This study was a correlational analytic with a 
cross-sectional design. The secondary data of 
medical records of all JNA patients at Dr. Hasan 
Sadikin General Hospital Bandung period 
2016–2019 was used, including the data of 
immunohistochemistry examination taken 
from paraffin blocks The study was conducted 
from May to October 2019. This study protocol 
was approved by the Ethics Committee of 
Hasan Sadikin Hospital no: LB.02.01/ X.6.5 / 
185/2019. 
Inclusion criteria were data of patients 
diagnosed with JNA, whereas the exclusion 
criteria were patients with residual or 
recurrent JNA and incomplete medical 
records. The patients were then divided into 
three stages, using Radkowski. Tumor size 
was determined based on tumor diameter ≤4 
cm and >4 cm.
The immunohistochemistry (IHC) 
examination of the paraffin block conducted 
in the Anatomical Pathology section of the 
Dr. Hasan Sadikin General Hospital was 
further classified according to the clinical 
stage. The VEGF expression was examined as 
followed: immunohistochemical smear with 
antibodies against VEGF was performed with 
the incubation with VEGF primary antibodies 
(mouse monoclonal antibody anti-human 
VEGF, 100 μg, PA1080, BosterBio-USA) with 
a 1:200 dilution for one night; the incubation 
with secondary antibodies for 30 minutes; 
the enzymatic detection system ABC (Avidin-
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Biotin Complex) using peroxidase, and DAB 
(Diamino Benzidin) enzymes as counterstain 
enzymes using Hematoxylin Eosin. The 
positive values were indicated by golden 
brown to the old color.
The expression of VEGF was assessed 
on the stromal and endothelial cells of the 
tumor and was counted visually with a multi-
headed binocular light microscope at 400x 
magnification performed by 2 examiners at 
the same time and preparation. The VEGF 
expression was further rated based on staining 
intensity, percentage distribution, and VEGF 
histoscore. The score for the intensity of cell 
absorption on IHC staining was divided into 
a score of 0 or negative/ when there was no 
VEGF expression, a score of 1+ or weak, a score 
of 2+ or moderate, 3+ or strong. Of all tumor 
cells expressing positive, the distribution 
percentage score was determined for <25% 
(1+), 26–50% (2+), 51–75% (3+), and >75% 
(4+) 
The VEGF expression was calculated 
semiquantitatively using the H-score formula 
with the formula [intensity x distribution]. 
The H score were 0 or negative, 1–4 as weakly 
positive, 5–8 as moderate positive, and 9–12 as 
strongly positive.
Results
In total, 24 data was retrieved diagnosed with 
JNA according to the inclusion and exclusion 
Table 1 Clinical Characteristic of Patients with 
Juvenile Nasopharyngeal Angiofibroma 
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     10–14
     15–19 




Mean (SD) 15.6 (3.4)
Range 11-24
Note: SD= standard deviation
Table 2 Relationship between Stage of Juvenile Nasopharyngeal Angiofibroma with VEGF 
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Note: VEGF= Vascular Endothelial Growth Factor; JNA, Juvenile Nasopharyngeal Angiofibroma; rs= Correlation 
Coefficient, *Spearman test p< 0.05; ** Histoscore in median
criteria, being the youngest age found was 
11 years and the oldest age was 24 years. 
The mean age was 15.6 years old (standard 
deviation, SD 3.4 years), as shown in Table 1.
The relationship between VEGF expression 
and tumor size according to the clinical 
stage as depicted in Table 2. The intensity 
ratio based on clinical stage showed a 
correlation coefficient (rs) of 0.414 (p=0.044, 
Spearman correlation test), indicating a 
significant relationship between the intensity 
of staining of VEGF expression to clinical 
stage. Furthermore, the percentage of VEGF 
distribution showed a significant correlation 
Althea Medical Journal. 2021;8(2)
90     Althea Medical Journal June 2021
with Spearman correlation of 0.832 (p<0.001) 
with the clinical stage.
The VEGF histoscore variable median for 
stage I, stage II, and stage III were 2.5, 6.5, and 
12, respectively. The rs the VEGF histoscore 
to the clinical stage was 0.723 (p=0.002), 
suggesting that there was a significant 
relationship between VEGF histoscore and 
VEGF expression variable at ANB clinical 
stage. The greater the VEGF histoscore value, 
the higher the clinical stage (Table 2). 
This study observed the intensity of the 
immunoreactivity and the percentage of 
positive cells that were initially estimated 
semi-quantitatively by light microscopy 
at 200x magnification in stromal cells and 
endothelial cells of JNA (Figure 1). Weak 
expression of VEGF was shown by pale brown 
color and positive cell distribution <25% 
(Figure 1A), while strong expression showed 
Figure 1 Intensity of Staining of VEGF Expression
A B






p-value*≤4 cm >4 cm
Age (year)
     10–14
     15–19












     Intensity of Staining
          Weak
          Strong
     Distribution Percentage
          <25%
          26–50%
          51–75%




























     Median 2 9.5 - 0.660
<0.001
 
Note: VEGF=Vascular Endothelial Growth Factor; rs= Correlation Coefficient, *Spearman test p< 0.05; ** Histoscore in 
median
Note: A= Weak Expression (IHC 200x) B= Strong Expression (IHC 200x)
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dark brown staining and cell distribution 
>75% (Figure 1B). Based on radiological 
examination using CT Scan, it showed that 
there was a relationship between tumor size 
and JNA stage with the correlation coefficient 
value of 0.6 (p=0.002, Spearman test).
The relationship between tumor size 
and age in JNA patients showed a significant 
correlation coefficient of 0.479 (p=0.018), 
as well the correlation between tumor size 
and VEGF staining intensity that showed 
a statistical of rs 0.529 (p=0.008). The 
correlation to percentage distribution was 
0.625 (p=0.001), and to the VEGF histoscore 
was 0.660 (p <0.001) (Table 3).
Discussion
Our study has explored the correlation 
between VEGF expression and the clinical stage 
of Juvenile Nasopharyngeal Angiofibroma 
(JNA) at Dr. Hasan Sadikin General Hospital 
Bandung period 2016–2019. The JNA patients 
are predominantly male in this study, with the 
most prevalent age group is between 10–15 
years old (54%), conforming to various studies 
in Malaysia17 as well in Jakarta, Indonesia.2 JNA 
has a predilection in the adolescent boys age 
range of 7–21 years with the highest incidence 
between the ages of 14–18 years and rarely 
at the age of 25 years.6 Although the etiology 
of nasopharyngeal angiofibroma is unknown, 
this might be related to hormonal imbalance,4,9 
such as an excess estrogen production or 
androgen deficiency.4,18 It seems that there is a 
relationship between tumors with the sex and 
age of the patient.7
In this study, strong staining (58.3%) and 
distribution percentage of >50% (75%) are 
the most predominant result of the VEGF 
examination. The VEGF expression has 
a significant correlation with the clinical 
stage (Table 2). Many studies had reported 
the escalation of VEGF expression in JNA, 
suggesting that the escalation of VEGF 
expression in JNA is correlated with the 
advanced clinical stage.10,15 However, another 
study has reported a different finding, VEGF 
expression had no significant correlation with 
clinical stage of JNA.16  
As a pro-angiogenic growth factor that 
has a prominent role in tumor biology, VEGF 
could induce vasculogenesis and angiogenesis. 
VEGF has a correlation with the increase 
of proliferation and the density of blood 
vessels.10 However, some others show that pro-
angiogenic factor in benign tumors has more 
effects towards blood vessel growth compared 
to tumor growth.19
The determination of the JNA stage is based 
on the results of a CT scan with contrast. The 
characteristic assessment of CT scans is tumor 
size. There is a relationship between tumor 
size and JNA clinical stage. High expression of 
VEGF also has influenced the increase in tumor 
size. The higher the level of VEGF expression, 
the larger the tumor size. Previous studies 
have shown similar results, angiogenesis 
affects tumor growth.1,18 In tumor growth, 
neovascularization has two effects; namely 
supplying nutrients and oxygen, and the newly 
formed endothelial cells that stimulate the 
growth of tumor cells around them, through 
the secretion of polypeptides such as PDGF, 
GM-CSF, and IL-1. In cancers with high cell 
proliferation, tumor growth is faster, showing 
that the larger tumor size the higher degree of 
histopathology.20
The limitation of the study is difficulty in 
getting JNA patients with stage I. Furthermore, 
the process of staining the IHC with antibodies 
to VEGF requires a long incubation time and 
dilution several times to get good results on 
sample readings. 
In conclusion, there is a strong correlation 
between increased VEGF expression and the 
JNA stage. Higher of VEGF expression may 
worsen the prognosis of JNA. Examination of 
VEGF expression can be used as a marker to 
assess the prognostic factors of JNA.
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